HK1208702A1 - Compositions and methods for modulation of fgfr3 expression fgfr3 - Google Patents

Compositions and methods for modulation of fgfr3 expression fgfr3

Info

Publication number
HK1208702A1
HK1208702A1 HK15109264.3A HK15109264A HK1208702A1 HK 1208702 A1 HK1208702 A1 HK 1208702A1 HK 15109264 A HK15109264 A HK 15109264A HK 1208702 A1 HK1208702 A1 HK 1208702A1
Authority
HK
Hong Kong
Prior art keywords
fgfr3
modulation
compositions
methods
expression
Prior art date
Application number
HK15109264.3A
Other languages
English (en)
Chinese (zh)
Inventor
馬伊‧黑特耶恩
瑟倫‧奧托松
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Publication of HK1208702A1 publication Critical patent/HK1208702A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
HK15109264.3A 2012-11-26 2015-09-21 Compositions and methods for modulation of fgfr3 expression fgfr3 HK1208702A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729922P 2012-11-26 2012-11-26
PCT/EP2013/074552 WO2014080004A1 (en) 2012-11-26 2013-11-25 Compositions and methods for modulation of fgfr3 expression

Publications (1)

Publication Number Publication Date
HK1208702A1 true HK1208702A1 (en) 2016-03-11

Family

ID=49639882

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109264.3A HK1208702A1 (en) 2012-11-26 2015-09-21 Compositions and methods for modulation of fgfr3 expression fgfr3

Country Status (12)

Country Link
US (1) US9725723B2 (ja)
EP (1) EP2922955B1 (ja)
JP (1) JP6463687B2 (ja)
KR (1) KR20150088305A (ja)
CN (1) CN104903448B (ja)
BR (1) BR112015012051A2 (ja)
CA (1) CA2889993A1 (ja)
DK (1) DK2922955T3 (ja)
HK (1) HK1208702A1 (ja)
MX (1) MX2015006289A (ja)
RU (1) RU2015120645A (ja)
WO (1) WO2014080004A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
BR112015012051A2 (pt) 2012-11-26 2017-12-12 Roche Innovation Ct Copenhagen As composições e métodos para modulação de expressão de fgfr3
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
MY193116A (en) 2014-01-16 2022-09-26 Wave Life Sciences Ltd Chiral design
KR20180118719A (ko) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
BR112020018697A2 (pt) 2018-03-19 2020-12-29 Taiho Pharmaceutical Co., Ltd. Composição farmacêutica incluindo alquilsulfato de sódio
JPWO2021153703A1 (ja) * 2020-01-31 2021-08-05
WO2022211095A1 (ja) * 2021-03-31 2022-10-06 ルクサナバイオテク株式会社 Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
AU2003290597A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DK3222722T3 (da) 2002-11-18 2019-06-17 Roche Innovation Ct Copenhagen As Antisense-design
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002856A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
CN101554074B (zh) 2006-10-30 2012-08-22 诺基亚公司 为用户设备提供运营商控制的移动性的方法、设备和系统
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
WO2009090182A1 (en) * 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
SI3702371T1 (sl) * 2009-03-25 2023-01-31 Genentech, Inc. Protitelesa proti FGFR3 in postopki za uporabo le-teh
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
BR112015012051A2 (pt) 2012-11-26 2017-12-12 Roche Innovation Ct Copenhagen As composições e métodos para modulação de expressão de fgfr3
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Also Published As

Publication number Publication date
JP2016501520A (ja) 2016-01-21
EP2922955A1 (en) 2015-09-30
EP2922955B1 (en) 2019-03-06
WO2014080004A1 (en) 2014-05-30
MX2015006289A (es) 2015-12-03
CN104903448B (zh) 2017-07-11
CN104903448A (zh) 2015-09-09
US20150307886A1 (en) 2015-10-29
BR112015012051A2 (pt) 2017-12-12
US9725723B2 (en) 2017-08-08
KR20150088305A (ko) 2015-07-31
RU2015120645A (ru) 2017-01-10
CA2889993A1 (en) 2014-05-30
JP6463687B2 (ja) 2019-02-06
DK2922955T3 (da) 2019-05-13

Similar Documents

Publication Publication Date Title
HK1251246A1 (zh) 用於使組合物脫硫的方法和組合物
HK1208702A1 (en) Compositions and methods for modulation of fgfr3 expression fgfr3
ZA201409229B (en) Compositions and methods for modulating utrn expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
EP2850187A4 (en) COMPOSITIONS AND METHODS FOR PTEN EXPRESSION MODULATION
EP2850184A4 (en) COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
EP2850183A4 (en) COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
HK1204330A1 (en) Factor viii compositions and methods of making and using same viii
EP2850190A4 (en) COMPOSITIONS AND METHOD FOR MODULATING MECP2 EXPRESSION
EP2850189A4 (en) COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
EP2849800A4 (en) COMPOUNDS AND METHOD FOR MODULATING BDNF EXPRESSION
IL237970A0 (en) Modulation of ire1
HK1204652A1 (en) Compositions and methods for modulation of atxn3 expression atxn3
EP2850182A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF ATP2A2
EP2836224A4 (en) COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
HK1205189A1 (en) Methods and compositions for modulating factor vii expression vii
PT3461895T (pt) Modulação da expressão de ube3a-ats
IL266882A (en) Compositions and methods for modulating ikbkap splicing
EP2827861A4 (en) COMPOSITION AND METHODS FOR CELLULAR MODULATION
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN
AU2012901658A0 (en) Compositions and methods of use

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE ADDRESS OF APPLICANT FROM FREMTIDSVEJ 3, 2970 HORSHOLM, GERMANY TO FREMTIDSVEJ 3, 2970 HORSHOLM, DENMARK

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221125